| Process |
| 1 | Breast cancer patients who received mammography or breast ultrasound before surgery |
| 2 | Breast cancer patients who had diagnosis in cytology and/or histology before surgery |
| 3 | Breast cancer patients who received ER and PR assessment before systemic therapy |
| 4 | HER2 assessment before systemic therapy |
| 5 | Stage I-II breast cancer patients who underwent breast-conserving surgery |
| 6 | Breast cancer patients who received sentinel lymph nodes biopsy |
| 7 | Breast cancer patients who received axillary lymph nodes dissection |
| 8 | Premenopausal breast cancer patients who were administrated adjuvant chemotherapy |
| 9 | Postmenopausal breast cancer patients with high risk who received Adjuvant chemotherapy |
| 10 | Breast cancer patients who were administrated at least four cycles of Adjuvant chemotherapy |
| 11 | Breast cancer patients treated by trastuzumab in whom heart function was monitored every 3 months |
| 12 | Breast cancer patient whose radiotherapy treatment was completed within a 7-week interval from the initiation of radiotherapy after breast-conserving surgery |
| 13 | Breast cancer patients who received standard dose of radiotherapy at the whole breast after breast-conserving surgery |
| 14 | Breast cancer patients who received adjuvant radiotherapy at chest wall |
| 15 | Breast cancer patients who received tamoxifen or aromatase inhibitor treatment |
| 16 | Breast cancer patients who received neo-adjuvant chemotherapy |
| 17 | Breast cancer patients with hormone receptor status of the tumor stated in Pathology report |
| 18 | Breast cancer patients with pathology report stated category of primary tumor and regional lymph nodes with histologic grade |
| 19 | Breast cancer patients with pathology report stated number of Examined lymph nodes and positive nodes |
| 20 | Breast cancer patients with hormone receptor status of the tumor Stated in pathology report |
| 21 | Breast cancer patients with tumor size documented in pathology report |
| Management of symptoms or treatment toxicity |
| 22 | Breast cancer patients who were administrated potent anti-emetic therapy |
| Communication and Cooperation |
| 23 | Breast cancer patients who were recommended for five-year endocrine treatment |
